JNJ
Johnson & Johnson
Healthcare · Drug Manufacturers - General · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- JNJ scores 71.6 primarily because its profitability sub-score is a perfect 20.0 out of 20, anchoring the total score with evidence of sustained high-margin pharmaceutical and MedTech operations as reported in the FY2025 10-K.
- The financial health sub-score of 18.0 out of 20 contributes significantly, reflecting strong leverage management and interest coverage ratios that are consistent with an investment-grade balance sheet structure.
- The dividend sub-score of 12.5 out of 20 adds meaningful points by capturing a verifiable track record of dividend per share growth and adequate free cash flow coverage, which aligns JNJ with its highest-fit research profile of dividend income at 77.0.
Why Not Higher
- The theme sub-score of 0.0 out of 20 is the single largest suppressant of the total score — had JNJ qualified for even two macro themes, the model would have added meaningful points that could have pushed the total above 80.
- The momentum sub-score of 13.0 out of 20 reflects that the most recent quarterly filing data does not show consistent acceleration in revenue or margin improvement, limiting the model's ability to award a higher score despite the strong longer-term profitability record.
Data Confidence
10 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Johnson & Johnson is one of the largest healthcare conglomerates in the United States, operating primarily through its pharmaceutical and MedTech segments following the 2023 spin-off of its consumer health division into Kenvue. The company's drug manufacturing operations span oncology, immunology, neuroscience, cardiovascular, and infectious disease therapies, while its MedTech segment covers surgical instruments, orthopedics, and vision care products. The model assigned JNJ a score of 71.6/100, reflecting a company with genuinely strong fundamentals across profitability and financial health — both scoring at or near their maximums — balanced against more moderate growth momentum and a dividend sub-score that, while solid, indicates some measured constraints on free cash flow distribution relative to peers. The absence of any macro theme exposure (0.0/20 on the theme sub-score) is the single largest drag on the total score, as the model found no qualifying thematic tailwinds such as AI, clean energy, or emerging market infrastructure that would elevate its speculative appeal. The core research tradeoff here is between a highly stable, financially robust dividend-oriented business and the limited upside from a growth and thematic momentum perspective — making it a well-suited research candidate for dividend income profiles but less compelling for speculative or high-growth mandates.
Plain English
Johnson & Johnson is a massive U.S. healthcare company that makes prescription drugs and medical devices used in hospitals and clinics around the world. A model score of 71.6 out of 100 means its financials are genuinely strong — particularly its profitability and balance sheet — but it is not scoring in the elite tier because its revenue growth and thematic exposure are more limited. The Medium risk rating reflects that while the company is financially stable, it carries real-world risks like drug patent cliffs, litigation exposure, and regulatory scrutiny that a researcher should not overlook. It ranks best as a dividend income research candidate rather than a high-growth or speculative opportunity.
Bull Case vs. Bear Case
Bull Case
- The profitability sub-score of 20.0 out of 20 indicates that JNJ's net margins, operating margins, and return on assets are among the strongest in its peer group as reported in the FY2025 10-K filing.
- The financial health sub-score of 18.0 out of 20 reflects a well-managed balance sheet with strong interest coverage and controlled leverage, suggesting the company is in a position to sustain operations and capital allocation through economic cycles.
- The dividend sub-score of 12.5 out of 20, combined with a best-fit profile score of 77.0 for dividend income, indicates a credible history of dividend per share growth and free cash flow coverage that supports ongoing income generation research interest.
Bear Case
- The growth sub-score of 15.0 out of 20 suggests that year-over-year revenue, net income, and EPS growth rates are solid but not exceptional, which limits the model's confidence in accelerating earnings trajectories for the post-Kenvue spin-off structure.
- The momentum sub-score of 13.0 out of 20 indicates that quarterly improvements in revenue, earnings, and margins have been inconsistent or modest based on the most recent filing data, implying near-term operating momentum is not a strong tailwind.
- The theme sub-score of 0.0 out of 20 means the model identified no macro thematic tailwinds — such as artificial intelligence integration, geopolitical supply chain shifts, or emerging market expansion — attached to JNJ's reported business lines, limiting its appeal in thematic screening contexts.
What Could Change the Picture
Bullish Triggers
- A meaningful acceleration in year-over-year revenue and EPS growth — particularly from new pharmaceutical launches in oncology or immunology as reported in subsequent 10-K filings — would raise the growth sub-score and improve the overall model score.
- Identification of qualifying macro thematic exposures, such as demonstrated AI-driven drug discovery integration or significant emerging market revenue expansion reported in future filings, would directly lift the theme sub-score from 0.0 and materially increase the total score.
Bearish Triggers
- A deterioration in operating margins or return on assets in future filings — potentially driven by patent expirations on key pharmaceutical products or increased R&D spend without corresponding revenue growth — would reduce the profitability sub-score from its current maximum.
- An increase in financial leverage or a decline in interest coverage ratios as reported in subsequent 10-K filings, potentially resulting from large acquisitions or elevated litigation settlement costs, would reduce the financial health sub-score and increase the assessed risk profile.
Red Flags
- The theme sub-score of 0.0 out of 20 represents a complete absence of identifiable macro theme exposure in the filing data, which structurally caps the total model score and reduces relevance to forward-looking thematic research mandates.
- The momentum sub-score of 13.0 suggests that quarterly financial improvement trends reported in the FY2025 10-K are not consistently positive, which could signal transitional pressure in the business following the consumer health spin-off.
Risk Profile
Medium RiskThe Medium risk rating for JNJ reflects that while its balance sheet and profitability are structurally strong, the company faces meaningful litigation overhang, pharmaceutical patent expiry risk on key revenue-generating drugs, and regulatory pricing pressure — all of which represent material uncertainties that prevent a Low risk classification despite its financial stability.
Key Catalysts to Watch
Key factors to monitor include new drug approval decisions from regulators for JNJ's late-stage oncology and immunology pipeline, as well as any material litigation resolution disclosures or changes in leverage reported in subsequent quarterly and annual SEC filings that could shift the financial health or dividend sub-scores.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.